Clinical Scorecard: Longitudinal Analysis of Metabolic Dysfunction-Associated Steatotic Liver Disease Patterns and Their Link to Liver Cancer Incidence: Findings from a UK Biobank Cohort

At a Glance

Key Highlights

• 33.1% of participants had MASLD at baseline.
• MASLD at both assessments was associated with higher liver cancer risk.
• Trajectory analyses indicated persistent MASLD and prior MASLD exposure increased liver cancer risk.

Guideline-Based Recommendations

Diagnosis

• MASLD defined by fatty liver index ≥60 plus one cardiometabolic risk criterion.

Management

• Monitor MASLD status over time to assess liver cancer risk.

Monitoring & Follow-up

• Regular health screenings to evaluate changes in MASLD status.

Risks

• Higher risk of liver cancer associated with MASLD at baseline and follow-up.

Patient & Prescribing Data

Participants from the UK Biobank cohort.

Focus on managing cardiometabolic risk factors in patients with MASLD.

Clinical Best Practices

• Utilize the fatty liver index for diagnosing MASLD.
• Consider longitudinal assessments for better risk stratification.

Related Resources & Content

• UK Biobank